Cited 0 times in 
Cited 1 times in 
Adjunctive administration of parabiotic Lactobacillus sakei CVL-001 ameliorates drug-induced toxicity and pulmonary inflammation during antibiotic treatment for tuberculosis
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | 신성재 | - |
| dc.date.accessioned | 2024-08-18T23:55:17Z | - |
| dc.date.available | 2024-08-18T23:55:17Z | - |
| dc.date.issued | 2024-05 | - |
| dc.identifier.issn | 1567-5769 | - |
| dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/200166 | - |
| dc.description.abstract | Tuberculosis (TB) treatment requires a long therapeutic duration and induces adverse effects such as hepatotoxicity, causing discontinuation of treatment. Reduced adherence to TB medications elevates the risk of recurrence and the development of drug resistance. Additionally, severe cavitary TB with a high burden of Mycobacterium tuberculosis (Mtb) and inflammation-mediated tissue damage may need an extended treatment duration, resulting in a higher tendency of drug-induced toxicity. We previously reported that the administration of Lactobacillus sakei CVL-001 (L. sakei CVL-001) regulates inflammation and improves mucosal barrier function in a murine colitis model. Since accumulating evidence has reported the functional roles of probiotics in drug-induced liver injury and pulmonary inflammation, we employed a parabiotic form of the L. sakei CVL-001 to investigate whether this supplement may provide beneficial effects on the reduction in drug-induced liver damage and pulmonary inflammation during chemotherapy. Intriguingly, L. sakei CVL-001 administration slightly reduced Mtb burden without affecting lung inflammation and weight loss in both Mtb-resistant and -susceptible mice. Moreover, L. sakei CVL-001 decreased T cell-mediated inflammatory responses and increased regulatory T cells along with an elevated antigen-specific IL-10 production, suggesting that this parabiotic may restrain excessive inflammation during antibiotic treatment. Furthermore, the parabiotic intervention significantly reduced levels of alanine aminotransferase, an indicator of hepatotoxicity, and cell death in liver tissues. Collectively, our data suggest that L. sakei CVL-001 administration has the potential to be an adjunctive therapy by reducing pulmonary inflammation and liver damage during anti-TB drug treatment and may benefit adherence to TB medication in lengthy treatment. | - |
| dc.description.statementOfResponsibility | restriction | - |
| dc.language | English | - |
| dc.publisher | Elsevier Science | - |
| dc.relation.isPartOf | INTERNATIONAL IMMUNOPHARMACOLOGY | - |
| dc.rights | CC BY-NC-ND 2.0 KR | - |
| dc.subject.MESH | Animals | - |
| dc.subject.MESH | Antitubercular Agents / adverse effects | - |
| dc.subject.MESH | Antitubercular Agents / therapeutic use | - |
| dc.subject.MESH | Chemical and Drug Induced Liver Injury / drug therapy | - |
| dc.subject.MESH | Chemical and Drug Induced Liver Injury / etiology | - |
| dc.subject.MESH | Chemical and Drug Induced Liver Injury / immunology | - |
| dc.subject.MESH | Female | - |
| dc.subject.MESH | Humans | - |
| dc.subject.MESH | Interleukin-10 / metabolism | - |
| dc.subject.MESH | Latilactobacillus sakei* | - |
| dc.subject.MESH | Liver / drug effects | - |
| dc.subject.MESH | Liver / immunology | - |
| dc.subject.MESH | Liver / pathology | - |
| dc.subject.MESH | Lung / drug effects | - |
| dc.subject.MESH | Lung / immunology | - |
| dc.subject.MESH | Lung / microbiology | - |
| dc.subject.MESH | Lung / pathology | - |
| dc.subject.MESH | Mice | - |
| dc.subject.MESH | Mice, Inbred BALB C | - |
| dc.subject.MESH | Mice, Inbred C57BL | - |
| dc.subject.MESH | Mycobacterium tuberculosis* / drug effects | - |
| dc.subject.MESH | Mycobacterium tuberculosis* / immunology | - |
| dc.subject.MESH | Pneumonia / drug therapy | - |
| dc.subject.MESH | Pneumonia / immunology | - |
| dc.subject.MESH | Probiotics* / administration & dosage | - |
| dc.subject.MESH | Probiotics* / therapeutic use | - |
| dc.subject.MESH | T-Lymphocytes, Regulatory / drug effects | - |
| dc.subject.MESH | T-Lymphocytes, Regulatory / immunology | - |
| dc.subject.MESH | Tuberculosis / drug therapy | - |
| dc.subject.MESH | Tuberculosis / immunology | - |
| dc.title | Adjunctive administration of parabiotic Lactobacillus sakei CVL-001 ameliorates drug-induced toxicity and pulmonary inflammation during antibiotic treatment for tuberculosis | - |
| dc.type | Article | - |
| dc.contributor.college | College of Medicine (의과대학) | - |
| dc.contributor.department | Dept. of Microbiology (미생물학교실) | - |
| dc.contributor.googleauthor | Hagyu Kim | - |
| dc.contributor.googleauthor | Eun-Jung Song | - |
| dc.contributor.googleauthor | Eunsol Choi | - |
| dc.contributor.googleauthor | Kee Woong Kwon | - |
| dc.contributor.googleauthor | Jong-Hwan Park | - |
| dc.contributor.googleauthor | Sung Jae Shin | - |
| dc.identifier.doi | 10.1016/j.intimp.2024.111937 | - |
| dc.contributor.localId | A02114 | - |
| dc.relation.journalcode | J01081 | - |
| dc.identifier.eissn | 1878-1705 | - |
| dc.identifier.pmid | 38569427 | - |
| dc.identifier.url | https://www.sciencedirect.com/science/article/pii/S1567576924004557 | - |
| dc.subject.keyword | Alanine aminotransferase | - |
| dc.subject.keyword | Antibiotic treatment | - |
| dc.subject.keyword | Hepatoxicity | - |
| dc.subject.keyword | Lactobacillus sakei CVL-001 | - |
| dc.subject.keyword | Tuberculosis | - |
| dc.contributor.alternativeName | Shin, Sung Jae | - |
| dc.contributor.affiliatedAuthor | 신성재 | - |
| dc.citation.volume | 132 | - |
| dc.citation.startPage | 111937 | - |
| dc.identifier.bibliographicCitation | INTERNATIONAL IMMUNOPHARMACOLOGY, Vol.132 : 111937, 2024-05 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.